🤝 argenx will acquire Forte Biosciences, Inc. for about $2.2B, adding FB102, a first-in-class anti-CD122 antibody with clinical validation in vitiligo and celiac disease. ✂️
💰 Entera Bio Ltd. raised an oversubscribed $275M private placement to fully fund Phase 3 development and NDA filing for oral osteoporosis candidate EB613, extending cash runway through 2030.
🫁 Gossamer Bio plans a September 2026 NDA filing for seralutinib in pulmonary arterial hypertension after FDA talks, while regaining full global rights from Chiesi and restructuring debt.
💰 Claris Biotherapeutics raised $118M Series B and hired new leadership to advance its limbal stem cell deficiency eye drug into late-stage testing next year.
❌ Capricor Therapeutics, Inc.’s Duchenne therapy deramiocel suffered a major FDA advisory setback, with panelists voting 9–3 that HOPE-3 data did not sufficiently prove efficacy.
🔄 Synlogic will merge with Caldera Therapeutics, backed by a $278M private placement, to create a Nasdaq-listed IBD biotech focused on TL1A/IL-23 bispecific antibody CLD-423.
🤝 Processa Pharmaceuticals acquired Vidya Therapeutics alongside a $200M private placement, adding oral CNS-penetrating BTK inhibitor VT-7208 for food allergy, chronic urticaria and multiple sclerosis studies.
🧫 Johnson & Johnson invested $785M upfront in Sail Biomedicines and secured a $2.58B acquisition option, expanding its push into in vivo cell therapy and immune-cell reprogramming.
📊 Ipsen sharply raised annual sales and profitability guidance after strong first-half results, now expecting more than 20% revenue growth at constant exchange rates.
📊 Bristol Myers Squibb now expects 2026 sales growth, lifting revenue guidance to $49B–$50B after stronger second-quarter results.
📊 Biogen posted a resilient quarter, beating Wall Street expectations with $2.7B in revenue and stronger-than-expected adjusted earnings.
📈 Replimune shares doubled after FDA advisers voted 10–3 in favor of RP1 efficacy in anti-PD-1 refractory melanoma.
📉 Novo Nordisk’s monthly ziltivekimab failed to reduce major cardiovascular events in Phase 3 despite lowering inflammatory markers, while serious infections increased.
📉 Alnylam Pharmaceuticals lost nearly $12B in market value after cutting 2026 guidance for its TTR amyloidosis franchise, citing normalized Amvuttra demand after an early launch spike.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.